PSI-7851, a Pronucleotide of β-D-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication

被引:120
作者
Lam, Angela M. [1 ]
Murakami, Eisuke [1 ]
Espiritu, Christine [1 ]
Steuer, Holly M. Micolochick [1 ]
Niu, Congrong [1 ]
Keilman, Meg [1 ]
Bao, Haiying [1 ]
Zennou, Veronique [1 ]
Bourne, Nigel [2 ]
Julander, Justin G. [3 ]
Morrey, John D. [3 ]
Smee, Donald F. [3 ]
Frick, David N. [4 ]
Heck, Julie A. [4 ]
Wang, Peiyuan [1 ]
Nagarathnam, Dhanapalan [1 ]
Ross, Bruce S. [1 ]
Sofia, Michael J. [1 ]
Otto, Michael J. [1 ]
Furman, Phillip A. [1 ]
机构
[1] Pharmasset Inc, Princeton, NJ 08540 USA
[2] Univ Texas Med Branch, Galveston, TX 77555 USA
[3] Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA
[4] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA
关键词
DEPENDENT RNA-POLYMERASE; EFFICIENT REPLICATION; ANTIVIRAL ACTIVITIES; SUBGENOMIC REPLICON; CROSS-RESISTANCE; PROGENITOR CELLS; PLUS RIBAVIRIN; NS5B PROTEIN; ANALOGS; EXPRESSION;
D O I
10.1128/AAC.00399-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The hepatitis C virus (HCV) NS5B RNA polymerase facilitates the RNA synthesis step during the HCV replication cycle. Nucleoside analogs targeting the NS5B provide an attractive approach to treating HCV infections because of their high barrier to resistance and pan-genotype activity. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine-5'-monophosphate, is a highly active nucleotide analog inhibitor of HCV for which a phase 1b multiple ascending dose study of genotype 1-infected individuals was recently completed (M. Rodriguez-Torres, E. Lawitz, S. Flach, J. M. Denning, E. Albanis, W. T. Symonds, and M. M. Berry, Abstr. 60th Annu. Meet. Am. Assoc. Study Liver Dis., abstr. LB17, 2009). The studies described here characterize the in vitro antiviral activity and cytotoxicity profile of PSI-7851. The 50% effective concentration for PSI-7851 against the genotype 1b replicon was determined to be 0.075 +/- 0.050 mu M (mean +/- standard deviation). PSI-7851 was similarly effective against replicons derived from genotypes 1a, 1b, and 2a and the genotype 1a and 2a infectious virus systems. The active triphosphate, PSI-7409, inhibited recombinant NS5B polymerases from genotypes 1 to 4 with comparable 50% inhibitory concentrations. PSI-7851 is a specific HCV inhibitor, as it lacks antiviral activity against other closely related and unrelated viruses. PSI-7409 also lacked any significant activity against cellular DNA and RNA polymerases. No cytotoxicity, mitochondrial toxicity, or bone marrow toxicity was associated with PSI-7851 at the highest concentration tested (100 mu M). Cross-resistance studies using replicon mutants conferring resistance to modified nucleoside analogs showed that PSI-7851 was less active against the S282T replicon mutant, whereas cells expressing a replicon containing the S96T/N142T mutation remained fully susceptible to PSI-7851. Clearance studies using replicon cells demonstrated that PSI-7851 was able to clear cells of HCV replicon RNA and prevent viral rebound.
引用
收藏
页码:3187 / 3196
页数:10
相关论文
共 58 条
[1]   Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479 [J].
Ali, Samir ;
Leveque, Vincent ;
Le Pogam, Sophie ;
Ma, Han ;
Philipp, Friederike ;
Inocencio, Nicole ;
Smith, Mark ;
Alker, Andre ;
Kang, Hyunsoon ;
Najera, Isabel ;
Klumpp, Klaus ;
Symons, Julian ;
Cammack, Nick ;
Jiang, Wen-Rong .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) :4356-4369
[2]   HCV natural history: The retrospective and prospective in perspective [J].
Alter, HJ .
JOURNAL OF HEPATOLOGY, 2005, 43 (04) :550-552
[3]  
[Anonymous], 43 ANN M EUR ASS STU
[4]  
[Anonymous], 60 ANN M AM ASS STUD
[5]  
[Anonymous], 58 ANN M AM ASS STUD
[6]   Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system [J].
Bourne, N ;
Pyles, RB ;
Yi, MK ;
Veselenak, RL ;
Davis, MM ;
Lemon, SM .
ANTIVIRAL RESEARCH, 2005, 67 (02) :76-82
[7]   A 2ND ORIGIN OF DNA PLUS-STRAND SYNTHESIS IS REQUIRED FOR OPTIMAL HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION [J].
CHARNEAU, P ;
ALIZON, M ;
CLAVEL, F .
JOURNAL OF VIROLOGY, 1992, 66 (05) :2814-2820
[8]   Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication [J].
Clark, JL ;
Mason, JC ;
Hollecker, L ;
Stuyver, LJ ;
Tharnish, PM ;
McBrayer, TR ;
Otto, MJ ;
Furman, PA ;
Schinazi, RF ;
Watanabe, KA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1712-1715
[9]  
Faster G, 2008, ANTIVIR THER, V13, P3
[10]   Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B [J].
Fleischer, Russell D. ;
Lok, Anna S. F. .
JOURNAL OF HEPATOLOGY, 2009, 51 (04) :787-791